Target Price | $4.00 |
Price | $0.35 |
Potential |
1,059.42%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Sensei Biotherapeutics Inc 2026 .
The average Sensei Biotherapeutics Inc target price is $4.00.
This is
1,059.42%
register free of charge
$4.00
1,059.42%
register free of charge
$4.00
1,059.42%
register free of charge
|
|
A rating was issued by 3 analysts: 3 Analysts recommend Sensei Biotherapeutics Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sensei Biotherapeutics Inc stock has an average upside potential 2026 of
1,059.42%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.20 | -0.69 |
1.64% | 42.50% | |
P/E | negative |
2 Analysts have issued a Sensei Biotherapeutics Inc forecast for earnings per share. The average Sensei Biotherapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Sensei Biotherapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
Oppenheimer |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 28 2025 |
Locked
Oppenheimer:
Locked
➜
Locked
|
Mar 28 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.